Senior Director, US New Product Planning

Vertex Inc.•Boston, MA

6d•$228,000 - $342,000•Hybrid

About The Position

We are seeking a Senior Director, US New Product Planning, to help shape the future of our pipeline and build the foundation for successful US launches. This is a highly visible leadership role for a strategic, commercially minded, and pragmatic leader who thrives at the intersection of asset strategy, US market planning, and enterprise capability building. This role is ideal for someone who has worked in both the US business and on global teams, and who understands what it takes to succeed in the US market across functions—not just within a single discipline. The individual will represent the US perspective for early pipeline assets, including assets approximately 3 to 4 years from launch, and help ensure that strategic decisions made today translate into successful launches tomorrow. Importantly, this role offers the opportunity to help build a new Business Unit for the organization. As the pipeline advances, this leader will help define the commercial foundation, capability needs, operating model, and resourcing approach required to establish a successful future US business.

Requirements

Significant experience in biotech or pharmaceutical commercial strategy, new product planning, marketing, launch strategy, or related roles
Meaningful experience in both: US commercial/business roles and global or enterprise asset/team roles
Demonstrated success in new product planning, pre-launch strategy, or launch planning
Deep experience in neurology and/or rare disease
Strong understanding of US commercialization in complex specialty markets, including buy-and-bill dynamics and related access, site-of-care, and reimbursement considerations
Experience building or shaping resourcing plans, operating models, and capability roadmaps
Proven ability to influence senior stakeholders and lead through a matrixed environment
Strong track record of cross-functional collaboration across commercial, medical, market access, analytics, operations, finance, and patient services

Nice To Haves

Experience in US commercial planning, brand leadership, or business leadership
Experience serving on a global asset team or in a global commercial strategy role
Experience in specialty markets and complex launch environments
Experience supporting assets from development through launch readiness
Experience with provider-administered therapies and commercialization models involving buy-and-bill

Responsibilities

Represent the US commercial perspective on global asset teams for early pipeline assets, especially those approximately 3 to 4 years from launch
Lead development of US commercial strategy in partnership with global commercial, medical, market access, HEOR, analytics, operations, and finance
Translate asset strategy into a clear US launch blueprint, including: market development priorities, launch scenarios and key assumptions, capability requirements, organization design implications, field force and non-personal promotion considerations, budget and investment needs
Identify and frame key strategic choices related to: positioning, patient finding and market development, access and reimbursement readiness, evidence generation priorities, customer engagement model, patient services and support strategy
Develop milestone-based and scenario-based plans that prepare the organization for launch well before traditional pre-launch planning begins
Partner with cross-functional leaders to define the capabilities, talent, processes, and infrastructure needed for launch success
Assess organizational readiness and recommend how to build, buy, or borrow required capabilities
Provide strategic input on US commercialization models, including implications for specialty, institution-based, and buy-and-bill markets
Support governance and executive decision-making with clear recommendations, tradeoffs, and risk assessments
Help ensure a smooth transition from early planning into launch readiness and in-market execution
Help define the strategic and organizational foundations of a new Business Unit